Efficient laboratory diagnosis of infectious diseases is increasingly important to clinical management and public health. Methods to directly detect nucleic acids of microbial pathogens in clinical specimens are rapid, sensitive, and may succeed when culturing the organism fails. Clinical syndromes are infrequently specific for single pathogens; thus, assays are needed that allow multiple agents to be simultaneously considered. Current multiplex assays employ gel-based formats in which products are distinguished by size, fluorescent reporter dyes that vary in color, or secondary enzyme hybridization assays. Gel-based assays are reported that detect 2--8 different targets with sensitivities of 2--100 PFU or \<1--5 PFU, depending on whether amplification is carried out in a single or nested format, respectively ([@R1]*--*[@R4]). Fluorescence reporter systems achieve quantitative detection with sensitivity similar to that of nested amplification; however, their capacity to simultaneously query multiple targets is limited to the number of fluorescent emission peaks that can be unequivocally resolved. At present, up to 4 fluorescent reporter dyes can be detected simultaneously ([@R5]*,*[@R6]). Multiplex detection of up to 9 pathogens has been achieved in hybridization enzyme systems; however, the method requires cumbersome postamplification processing ([@R7]).

The Study
=========

To address the need for sensitive multiplex assays in diagnostic molecular microbiology, we created a polymerase chain reaction (PCR) platform in which microbial gene targets are coded by a library of 64 distinct Masscode tags (Qiagen Masscode technology, Qiagen, Hilden, Germany). A schematic representation of this approach is shown in [Figure 1](#F1){ref-type="fig"}. Microbial nucleic acids (RNA, DNA, or both) are amplified by multiplex reverse transcription (RT)-PCR using primers labeled by a photocleavable link to molecular tags of different molecular weight. After removing unincorporated primers, tags are released by UV irradiation and analyzed by mass spectrometry. The identity of the microbe in the clinical sample is determined by its cognate tags.

![Schematic representation of Mass Tag polymerase chain reaction (PCR).](04-0492-F1){#F1}

As a first test of this technology, we focused on respiratory disease because differential diagnosis is a common clinical challenge, with implications for outbreak control and individual case management. Multiplex primer sets were designed to identify up to 22 respiratory pathogens in a single Mass Tag PCR reaction; sensitivity was established by using synthetic DNA and RNA standards as well as titered viral stocks; the utility of Mass Tag PCR was determined in blinded analysis of previously diagnosed clinical specimens.

Oligonucleotide primers were designed in conserved genomic regions to detect the broadest number of members for a given pathogen species by efficiently amplifying a 50- to 300-bp product. In some instances, we selected established primer sets; in others, we used a software program designed to cull sequence information from GenBank, perform multiple alignments, and maximize multiplex performance by selecting primers with uniform melting temperatures and minimal cross-hybridization potential ([Table A1](#TA.1){ref-type="table"}). Primers, synthesized with a 5´ C6 spacer and aminohexyl modification, were covalently conjugated by a photocleavable link to Masscode tags (Qiagen Masscode technology) ([@R8]*,*[@R9]). Masscode tags have a modular structure, including a tetrafluorophenyl ester for tag conjugation to primary amines; an o-nitrobenzyl photolabile linker for photoredox cleavage of the tag from the analyte; a mass spectrometry sensitivity enhancer, which improves the efficiency of atmospheric pressure chemical ionization of the cleaved tag; and a variable mass unit for variation of the cleaved tag mass ([@R8]*,*[@R10]*--*[@R12]). A library of 64 different tags has been established. Forward and reverse primers in individual primer sets are labeled with distinct molecular weight tags. Thus, amplification of a microbial gene target produces a dual signal that allows assessment of specificity.

Gene target standards were cloned by PCR into pCR2.1-TOPO (Invitrogen, Carlsbad, CA, USA) by using DNA template (bacterial and DNA viral targets) or cDNA template (RNA viral targets) obtained by reverse transcription of extracts from infected cultured cells or by assembly of overlapping synthetic polynucleotides. Assays were initially established by using plasmid standards diluted in 2.5-µg/mL human placenta DNA (Sigma, St. Louis, MO, USA) and subjected to PCR amplification with a multiplex PCR kit (Qiagen), primers at 0.5 µmol/L each, and the following cycling protocol: an annealing step with a temperature reduction in 1°C increments from 65°C to 51°C during the first 15 cycles and then continuing with a cycling profile of 94°C for 20 s, 50°C for 20 s, and 72°C for 30 s in an MJ PTC200 thermal cycler (MJ Research, Waltham, MA, USA). Amplification products were separated from unused primers by using QIAquick 96 PCR purification cartridges (Qiagen, with modified binding and wash buffers). Masscode tags were decoupled from amplified products through UV light-induced photolysis in a flow cell and analyzed in a single quadrapole mass spectrometer using positive-mode atmospheric pressure chemical ionization (Agilent Technologies, Palo Alto, CA, USA). A detection threshold of 100 DNA copies was determined for 19 of 22 cloned targets by using a 22-plex assay ([Table 1](#T1){ref-type="table"}).

###### Sensitivity of pathogen detection by Mass Tag polymerase chain reaction determined by using plasmid and synthetic RNA standards\*

  Pathogen or protein        Detection threshold (DNA copies/RNA copies)
  -------------------------- ---------------------------------------------
  Influenza A matrix         100/1,000
  Influenza A N1             100/NA
  Influenza A N2             100/NA
  Influenza A H1             100/NA
  Influenza A H2             100/NA
  Influenza A H3             100/NA
  Influenza A H5             100/NA
  Influenza B H              500/1,000
  RSV group A                100/1,000
  RSV group B                100/500
  Metapneumovirus            100/1,000
  CoV-SARS                   100/500
  CoV-OC43                   100/500
  CoV-229E                   100/500
  HPIV-1                     100/1,000
  HPIV-2                     100/1,000
  HPIV-3                     100/500
  *Chlamydia pneumoniae*     100/NA
  *Mycoplasma pneumoniae*    100/NA
  *Legionella pneumophila*   100/NA
  *Enterovirus* (genus)      500/1,000
  *Adenovirus* (genus)       5,000/NA

\*NA, not assessed; RSV, respiratory syncytial virus; CoV, coronavirus; SARS, severe acute respiratory syndrome; HPIV, human parainfluenza virus.

Many respiratory pathogens have RNA genomes; thus, where indicated, assay sensitivity was determined by using synthetic RNA standards or RNA extracts of viral stocks. Synthetic RNA standards were generated by using T7 polymerase and linearized plasmid DNA. After quantitation by UV spectrometry, RNA was serially diluted in 2.5-µg/mL yeast tRNA (Sigma), reverse transcribed with random hexamers by using Superscript II (Invitrogen, Carlsbad, CA, USA), and used as template for Mass Tag PCR. As anticipated, sensitivity was reduced by the use of RNA instead of DNA templates ([Table 1](#T1){ref-type="table"}). The sensitivity of Mass Tag PCR to detect live virus was tested by using RNA extracted from serial dilutions of titered stocks of coronaviruses (severe acute respiratory syndrome \[SARS\] and OC43) and parainfluenzaviruses (HPIV 2 and 3). A 100-µL volume of each dilution was analyzed. RNA extracted from a 1-TCID~50~/mL dilution, representing 0.025 TCID~50~ per PCR reaction, was consistently positive in Mass Tag PCR.

RNA extracted from banked sputum, nasal swabs, and pulmonary washes of persons with respiratory infection was tested by using an assay panel comprising 30 gene targets that represented 22 respiratory pathogens. Infection in each of these persons had been previously diagnosed through virus isolation, conventional nested RT-PCR, or both. Reverse transcription was performed using random hexamers, and Mass Tag PCR results were consistent in all cases with the established diagnosis. Infections with respiratory syncytial virus, human parainfluenza virus, SARS coronavirus, adenovirus, enterovirus, metapneumovirus, and influenza virus were correctly identified ([Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). A panel comprising gene targets representing 17 pathogens related to central nervous system infectious disease (influenza A virus matrix gene; influenza B virus; human coronaviruses 229E, OC43, and SARS; enterovirus; adenovirus; human herpesvirus-1 and -3; West Nile virus; St. Louis encephalitis virus; measles virus; HIV-1 and -2; and *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Nesseria meningitidis*) was applied to RNA obtained from banked samples of cerebrospinal fluid and brain tissue that had been previously characterized by conventional diagnostic RT-PCR. Two of 3 cases of West Nile virus encephalitis were correctly identified. Eleven of 12 cases of enteroviral meningitis were detected representing serotypes CV-B2, CV-B3, CV-B5, E-6, E-11, E-13, E-18, and E-30 (data not shown).

###### Multiplex pathogen detection by Mass Tag polymerase chain reaction using Masscode-labeled primers in a 30-plex assay with clinical specimens with previously identified pathogens\*

  Pathogen          No. positive/no. tested†
  ----------------- --------------------------
  RSV A             2/2
  RSV B             3/3
  HPIV-1            1/1
  HPIV-3            2/2
  HPIV-4            2/2
  CoV-SARS          4/4
  Metapneumovirus   2/3
  Influenza B       1/3
  Influenza A       2/6
  Adenovirus        2/2
  Enterovirus       2/2

\*RSV, respiratory syncytial virus; HPIV, human parainfluenza virus; CoV, coronavirus; SARS, severe acute respiratory syndrome. †No. positive and consistent with previous diagnosis/number tested (with respective previous diagnosis).

![Analysis of clinical specimens. RNA extracts from clinical specimens containing known pathogens were reverse transcribed into cDNA (Superscript RT system, Invitrogen, Carlsbad, CA; 20-µL volume). Five microliters of the reaction were subjected to Mass Tag PCR by using primers coupled to Masscode tags (Qiagen Masscode technology, Qiagen, Hilden, Germany). Detection of (A) influenza virus A (H1N1), (B) respiratory syncytial virus (RSV) group B, (C) human coronavirus SARS (HCoV-SARS), (D) human parainfluenza virus (HPIV) types 1 and (E) 3, and (F) enterovirus (EV) by using a 30-plex assay, including 60 primers targeting influenza A virus matrix gene (FLUAV-M), and for typing N1, N2, H1, H2, H3, and H5 sequences, as well as influenza B virus (FLUBV), RSV groups A and B, HCoV-229E, -OC43, and -SARS, HPIV types 1, 2, 3, and 4 (groups A and B combined; 4 primers), human metapneumovirus (HMPV, 4 primers), measles virus (MEV), EV (degenerate primer pair targeting all serogroups), human adenoviruses (HAdV, degenerate primer pair targeting all serogroups), human herpesvirus 1 (HHV-1, herpes simplex virus), human herpesvirus 3 (HHV-3; varicella-zoster virus), *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella pneumophila*, *Streptococcus pneumoniae*, *Haemophilus influenzae*. The bar indicates an arbitrary cut-off threshold of 2.7 (4 times average background determined with random human DNA).](04-0492-F2){#F2}

Conclusions
===========

Our results indicate that Mass Tag PCR is a sensitive and specific tool for molecular characterization of microflora. The advantage of Mass Tag PCR is its capacity for multiplex analysis. Although the use of degenerate primers (e.g., enteroviruses and adenoviruses, [Table A1](#TA.1){ref-type="table"} and [Table 1](#T1){ref-type="table"}) may reduce sensitivity, the limit of multiplexing to detect specific targets will likely be defined by the maximal primer concentration that can be accommodated in a PCR mix. Analysis requires the purification of product from unincorporated primers and mass spectroscopy. Although these steps are now performed manually, and mass spectrometers are not yet widely distributed in clinical laboratories, the increasing popularity of mass spectrometry in biomedical sciences and the advent of smaller, lower-cost instruments could facilitate wider use and integrated instrumentation. In addition to developing additional pathogen panels, our continuing work is focused on optimizing multiplexing, sensitivity, and throughput. Potential applications include differential diagnosis of infectious diseases, blood product surveillance, forensic microbiology, and biodefense.
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###### Respiratory panel Mass Tag primers.

  Target -- Masscode FWD/REV          Name FWD        Sequence                       Name REV        Sequence                            Ref.
  ----------------------------------- --------------- ------------------------------ --------------- ----------------------------------- ----------
  FLUAV-M 618/690                     AM-U151         CATGGAATGGCTAAAGACAAGACC       AM-L397         AAGTGCACCAGCAGAATAACTGAG            ([@R8])
  FLUAV-N1 499/439                    NA1-U1078       ATGGTAATGGTGTTTGGATAGGAAG      NA1-L1352       AATGCTGCTCCCACTAGTCCAG              ([@R8])
  FLUAV-N2 658/730                    NA2-U560        AAGCATGGCTGCATGTTTGTG          NA2-L858        ACCAGGATATCGAGGATAACAGGA            ([@R8])
  FLUAV-HA1 650/590                   HA1-U583        GGTGTTCATCACCCGTCTAACAT        HA1-L895        GTGTTTGACACTTCGCGTCACAT             ([@R8])
  FLUAV-HA2 662/539                   H2A208U27       GCTATGCAAACTAAACGGAATYCCTCC    H2A559L26       TATTGTTGTACGATCCTTTGGCAACC          
  FLUAV-HA3-1 586/475                 HA3-U115        GCTACTGAGCTGGTTCAGAGTTC        HA3-L375        GAAGTCTTCATTGATAAACTCCAG            ([@R8])
  FLUAV-HA5 646/395                   HA5hum-u71      TTACTGTTACACATGCCCAAGACA       HA5hum-L147     AGGYTTCACTCCATTTAGATCGCA            
  FLUBV 698/598                       BHA-U188        AGACCAGAGGGAAACTATGCCC         BHA-L347        CTGTCGTGCATTATAGGAAAGCAC            ([@R8])
  HCoV-SARS 527/666                   CIID-28891F     AAGCCTCGCCAAAAACGTAC           CIID-29100R     AAGTCAGCCATGTTCCCGAA                
  HCoV-229E 670/558                   Taq-Co22-418F   GGCGCAAGAATTCAGAACCA           Taq-Co22-636R   TAAGAGCCGCAGCAACTGC                 
  HCoV-OC43 686/548                   Taq-Co43-270F   TGTGCCTATTGCACCAGGAGT          Taq-Co43-508R   CCCGATCGACAATGTCAGC                 
  RSV A 467/455                       RSA-U1137       AGATCAACTTCTGTCATCCAGCAA       RSV-L1192       GCACATCATAATTAGGAGTATCAAT           ([@R9])
  RSV B 483/479                       RSB-U1248       AAGATGCAAATCATAAATTCACAGGA     RSV-1318        TGATATCCAGCATCTTTAAGTATCTTTATAGTG   ([@R9])
  HMPV-1 718/654                      MPV01.2         AACCGTGTACTAAGTGATGCACTC       MPV02.2         CATTGTTTGACCGGCCCCATAA              ([@R10])
  HMPV-2 718/654                      MV-Can-U918     AAGTCCAAAGGCAGGRCTGTTATC       MV-Can-L992     CCTGAAGCATTRCCAAGAACAACAC           
  HPIV-1 566/357                      HPIV1-U82       TACTTTTGACACATTTAGTTCCAGGAG    HPIV1-L167      CGGTACTTCTTTGACCAGGTATAATTG         
  HPIV-2 463/590                      HPIV2-U908      GGACTTGGAACAAGATGGCCT          HPIV2-L984      AGCATGAGAGCYTTTAATTTCTGGA           
  HPIV-3 423/539                      HPIV3-U590      GCTTTCAGACAAGATGGAACAGTG       HPIV3-L668      GCATKATTGACCCAATCTGATCC             
  HPIV 4A 622/606                     HPIV4A-U191     AACAGAAGGAAATGATGGTGGAAC       HPIV4A-L269     TGCTGTGGATGTATGGGCAG                
  HPIV 4B 622/606                     HPIV4B-U194     AGAAGAAAACAACGATGAGACAAGG      HPIV4B-L306     GTTTCCCTGGTTCACTCTCTTCA             
  Measles 578/562                     MEA-U1103       CAAGCATCATGATYGCCATTCCTGG      MEA-L1183       CCTGAATCYCTGCCTATGATGGGTTT          
  Adenovirus 503/630                  ADV2HEX2F       CCCMTTYAACCACCACCG             ADVHEX1R        ACATCCTTBCKGAAGTTCCA                ([@R11])
  Enterovirus 702/495                 5UTR-U447       TCCTCCGGCCCCTGAATGCGGCTAATCC   5UTR-L541       GAAACACGGWCACCCAAAGTASTCG           
  HHV-1 443/706                       HSV-U27         CCCGGATGCGGTCCAGACGATTAT       HSV-L121        CCCGCGGAGGTTGTACAAAAAGCT            
  HHV-3 515/471                       VZV-U138        ACGTGGATCGTCGGATCAGTTGT        VZV-L196        TCGCTATGTGCTAAAACACGCGG             
  *Legionella pneumophila* 678/582    LegPneu-U149    GCATWGATGTTARTCCGGAAGCA        LegPneu-L223    CGGTTAAAGCCAATTGAGCG                
  *Chlamydia pneumoniae* 519/383      CLPM1           CATGGTGTCATTCGCCAAGT           CLPM2           CGTGTCGTCCAGCCATTTTA                ([@R12])
  *Streptococcus pneumonia* 714/694   SPPLY-U532      AGCGATAGCTTTCTCCAAGTGG         SPPLY-L606      CTTAGCCAACAAATCGTTTACCG             
  *Haemophilus influenzae* 734/726    HINF-U82        AAGCTCCTTGMATTTTTTGTATTAGAA    Hinf-L158       GCTGAATTGGCTTRGATACCGAG             
  *Mycoplasma pneumoniae* 602/614     MTPM1           CCAACCAAACAACAACGTTCA          MTPM2           ACCTTGACTGGAGGCCGTTA                ([@R12])
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